Hormones & metabolism Somatostatin analog
Pasireotide
Regulatory status
Status at a glance
503A compounding status
Not nominated
We found no pending nomination for the 503A bulks list. Unless the substance has another legal pathway (for example, a USP monograph or use in an FDA-approved drug), 503A pharmacies generally may not compound with it.
- Also known as
- Signifor
- FDA approval
- An FDA-approved product contains this peptide
- 503B outsourcing
- Not determined
- Anti-doping (WADA)
- Not on the WADA Prohibited List
- DEA schedule
- Not a controlled substance
About peptide status
Most peptides discussed here are not FDA-approved for any use, and products labeled “research use only” are not for human use. Removal from Category 2 does not authorize compounding. PCAC votes are non-binding recommendations; FDA and HHS make the final decisions.
This is not medical or legal advice, and we do not publish dosing, sourcing or reconstitution information. Talk with a licensed clinician before using any peptide.
If you think you are having a medical emergency, call 911.
Key takeaway
Pasireotide (sold as Signifor and Signifor LAR) is a somatostatin analog that binds a broader set of somatostatin receptors than older drugs in its class, which makes it useful in Cushing's disease as well as acromegaly. In a 12-month phase 3 trial in Cushing's disease it reduced urinary free cortisol and normalized it in some patients. It has been FDA-approved in the U.S. since 2012, and its most notable side effect is high blood sugar.
At a glance
- What it is
- A multireceptor-targeted somatostatin analog peptide
- Approved for
- Cushing's disease and acromegaly
- Key fact
- In a 12-month phase 3 trial it normalized urinary free cortisol in a subset of Cushing's disease patients
- Route
- Subcutaneous twice daily (Signifor) or monthly intramuscular depot (Signifor LAR)
- Evidence strength
- FDA approved
Summary
Pasireotide (Signifor) is an FDA-approved somatostatin analog for Cushing's disease and acromegaly. Learn how it works and why it raises blood sugar.
What is pasireotide?
Pasireotide, sold as Signifor (twice-daily injection) and Signifor LAR (monthly depot), is a synthetic cyclohexapeptide analog of somatostatin. What sets it apart from octreotide and lanreotide is its broader receptor profile: it binds four of the five somatostatin receptor subtypes, with especially high affinity for subtype 5. That breadth lets it act on tumors that older analogs reach poorly. It was developed under the code SOM230 and approved in the United States in 2012.
How does pasireotide work?
Pasireotide binds multiple somatostatin receptor subtypes, most importantly subtype 5, which is highly expressed on the corticotroph tumors that cause Cushing's disease. Activating those receptors suppresses the tumor's secretion of adrenocorticotropic hormone (ACTH), which in turn lowers cortisol production by the adrenal glands. In acromegaly, the same broad receptor activation suppresses growth hormone and insulin-like growth factor 1.
This receptor breadth is the reason pasireotide is used when other somatostatin analogs are inadequate. In a 12-month phase 3 trial in Cushing's disease, pasireotide reduced and in some patients normalized urinary free cortisol, with a greater effect at the higher dose. A notable trade-off is that pasireotide raises blood glucose more than other somatostatin analogs, because its receptor activity reduces insulin secretion.
Is it FDA-approved?
Editor’s note
Status: Yes. Pasireotide was approved by the FDA in stages: Year | Product | Approved for 2012 | Signifor | Cushing's disease when surgery is not an option or has not worked 2014 | Signifor LAR (long-acting) | Acromegaly Later | Signifor LAR (long-acting) | Cushing's disease
Category: FDA-approved · Primary body area: Hormones & metabolism
Yes. Pasireotide was approved by the FDA in stages:
| Year | Product | Approved for |
|---|---|---|
| 2012 | Signifor | Cushing's disease when surgery is not an option or has not worked |
| 2014 | Signifor LAR (long-acting) | Acromegaly |
| Later | Signifor LAR (long-acting) | Cushing's disease |
What is pasireotide prescribed for?
Pasireotide is prescribed for Cushing's disease in adults for whom pituitary surgery is not curative or not possible, and for acromegaly inadequately controlled by surgery or other therapy.
What are the side effects?
According to the prescribing information, common side effects include:
- High blood sugar and new-onset diabetes, which can be pronounced
- Diarrhea and nausea
- Gallstones
- Headache, abdominal pain, and fatigue
More serious considerations include:
- Significant hyperglycemia requiring glucose monitoring and treatment
- Slowed heart rate and QT-interval prolongation
- Elevated liver enzymes and low cortisol if suppression is excessive
Sources: FDA prescribing information for Signifor and Signifor LAR; the phase 3 Cushing's disease trial (Colao et al., New England Journal of Medicine, 2012, DOI: 10.1056/NEJMoa1105743), indexed on PubMed. This document is educational and does not constitute medical advice.
Registered human trials
0 registered human trials on ClinicalTrials.gov that we reviewed
Sources
- [1]
- [2]
approved (PDF)
Compare every peptide’s status in the peptide regulatory status database
More for Hormones & metabolism
View all hormones & metabolism peptides →- FDA-approved Hormones & metabolism
Albiglutide
Albiglutide is a once-weekly GLP-1 receptor agonist made by fusing GLP-1 analog chains to human albumin, approved for type 2 diabetes in 2014 as Tanzeum. It had a somewhat weaker effect on gastric emptying and appetite than some other GLP-1 drugs but showed a cardiovascular benefit in the HARMONY OUTCOMES trial. Despite that, GSK withdrew it from the market in 2018 for commercial reasons, so it remains FDA-approved but is no longer available.
- Not FDA-approved Hormones & metabolism
Compounded-Tesamorelin
Tesamorelin is an FDA-approved growth-hormone-releasing peptide, sold as Egrifta, for excess abdominal fat in HIV-associated lipodystrophy. In a randomized trial of 404 people with HIV (Falutz 2010), visceral fat fell 10.9% on tesamorelin versus 0.6% on placebo over 6 months. Its off-label use for body composition and anti-aging in people without HIV is not an approved indication and lacks dedicated trials. It is banned in sport.
- FDA-approved Hormones & metabolism
Corticotropin
ACTH
Corticotropin (adrenocorticotropic hormone, or ACTH; sold as Acthar Gel and Purified Cortrophin Gel) is a hormone preparation that stimulates the adrenal glands to make their own steroids and also acts directly on immune cells. It is one of the oldest biologic medicines, used today for conditions ranging from infantile spasms to multiple sclerosis relapses. It has been FDA-approved in the U.S. since 1952 and is given as a long-acting injection.
- FDA-approved Hormones & metabolism
Cosyntropin
Cosyntropin (sold as Cortrosyn) is a synthetic fragment of adrenocorticotropic hormone used as a diagnostic agent to test whether the adrenal glands are working. A dose is given and the resulting rise in cortisol shows how well the adrenals respond. It has long been FDA-approved in the U.S. and is given as a single injection during the test.
- FDA-approved Hormones & metabolism
Dulaglutide
Dulaglutide is a once-weekly GLP-1 receptor agonist built by fusing two GLP-1 analog chains to an antibody fragment, which extends its action to about five days. It was approved for type 2 diabetes in 2014 and gained a cardiovascular indication in 2020 after the REWIND trial showed a roughly 12% reduction in major cardiovascular events. It remains on the market as Trulicity.
- In clinical trials Hormones & metabolism
Efpeglenatide
Efpeglenatide is an investigational long-acting GLP-1 receptor agonist, originally developed by Hanmi Pharmaceutical, given as a once-weekly injection for type 2 diabetes and cardiovascular risk. In a large Phase 3 outcomes trial it reduced major cardiovascular events in people with type 2 diabetes. As of 2026, it has not reached approval in major markets.